165 related articles for article (PubMed ID: 35219595)
1. Pro-resolving therapies as potential adjunct treatment for infectious diseases: Evidence from studies with annexin A1 and angiotensin-(1-7).
Tavares LP; Melo EM; Sousa LP; Teixeira MM
Semin Immunol; 2022 Jan; 59():101601. PubMed ID: 35219595
[TBL] [Abstract][Full Text] [Related]
2. Harnessing inflammation resolving-based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID-19?
Sousa LP; Pinho V; Teixeira MM
Br J Pharmacol; 2020 Sep; 177(17):3898-3904. PubMed ID: 32557557
[TBL] [Abstract][Full Text] [Related]
3. Resolution Pharmacology: Focus on Pro-Resolving Annexin A1 and Lipid Mediators for Therapeutic Innovation in Inflammation.
Perretti M; Dalli J
Annu Rev Pharmacol Toxicol; 2023 Jan; 63():449-469. PubMed ID: 36151051
[TBL] [Abstract][Full Text] [Related]
4. Exploiting the pro-resolving actions of glucocorticoid-induced proteins Annexin A1 and GILZ in infectious diseases.
Vago JP; Tavares LP; Riccardi C; Teixeira MM; Sousa LP
Biomed Pharmacother; 2021 Jan; 133():111033. PubMed ID: 33378946
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Potential of Annexin A1 in Ischemia Reperfusion Injury.
Ansari J; Kaur G; Gavins FNE
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29659553
[TBL] [Abstract][Full Text] [Related]
6. Annexin A1 and specialized proresolving lipid mediators: promoting resolution as a therapeutic strategy in human inflammatory diseases.
Perucci LO; Sugimoto MA; Gomes KB; Dusse LM; Teixeira MM; Sousa LP
Expert Opin Ther Targets; 2017 Sep; 21(9):879-896. PubMed ID: 28786708
[TBL] [Abstract][Full Text] [Related]
7. Resolution of inflammation in neuromyelitis optica spectrum disorders.
Wang X; Jiao W; Lin M; Lu C; Liu C; Wang Y; Ma D; Wang X; Yin P; Feng J; Zhu J; Zhu M
Mult Scler Relat Disord; 2019 Jan; 27():34-41. PubMed ID: 30300851
[TBL] [Abstract][Full Text] [Related]
8. Annexin A1 promotes timely resolution of inflammation in murine gout.
Galvão I; Vago JP; Barroso LC; Tavares LP; Queiroz-Junior CM; Costa VV; Carneiro FS; Ferreira TP; Silva PM; Amaral FA; Sousa LP; Teixeira MM
Eur J Immunol; 2017 Mar; 47(3):585-596. PubMed ID: 27995621
[TBL] [Abstract][Full Text] [Related]
9. Relevance of angiotensin-(1-7) and its receptor Mas in pneumonia caused by influenza virus and post-influenza pneumococcal infection.
Melo EM; Del Sarto J; Vago JP; Tavares LP; Rago F; Gonçalves APF; Machado MG; Aranda-Pardos I; Valiate BVS; Cassali GD; Pinho V; Sousa LP; A-Gonzalez N; Campagnole-Santos MJ; Bader M; Santos RAS; Machado AV; Ludwig S; Teixeira MM
Pharmacol Res; 2021 Jan; 163():105292. PubMed ID: 33171305
[TBL] [Abstract][Full Text] [Related]
10. Annexin A1 and resolution of inflammation: tissue repairing properties and signalling signature.
Gobbetti T; Cooray SN
Biol Chem; 2016 Oct; 397(10):981-93. PubMed ID: 27447237
[TBL] [Abstract][Full Text] [Related]
11. Annexin A1 based inflammation resolving mediators and nanomedicines for inflammatory bowel disease therapy.
Xu R; Weber MC; Hu X; Neumann PA; Kamaly N
Semin Immunol; 2022 Nov; 61-64():101664. PubMed ID: 36306664
[TBL] [Abstract][Full Text] [Related]
12. Exploiting the Annexin A1 pathway for the development of novel anti-inflammatory therapeutics.
Perretti M; Dalli J
Br J Pharmacol; 2009 Oct; 158(4):936-46. PubMed ID: 19845684
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological strategies to resolve acute inflammation.
Sousa LP; Alessandri AL; Pinho V; Teixeira MM
Curr Opin Pharmacol; 2013 Aug; 13(4):625-31. PubMed ID: 23578762
[TBL] [Abstract][Full Text] [Related]
14. Resolution of inflammation: mechanisms and opportunity for drug development.
Alessandri AL; Sousa LP; Lucas CD; Rossi AG; Pinho V; Teixeira MM
Pharmacol Ther; 2013 Aug; 139(2):189-212. PubMed ID: 23583354
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of pro-resolving mediators in diabetic kidney disease.
Vartak T; Godson C; Brennan E
Adv Drug Deliv Rev; 2021 Nov; 178():113965. PubMed ID: 34508793
[TBL] [Abstract][Full Text] [Related]
16. Specialized proresolution mediators in the bladder: annexin-A1 normalizes inflammation and bladder dysfunction during bladder outlet obstruction.
Hughes FM; Harper SN; Nosé BD; Allkanjari A; Zheng MT; Jin H; Purves JT
Am J Physiol Renal Physiol; 2021 Oct; 321(4):F443-F454. PubMed ID: 34396790
[TBL] [Abstract][Full Text] [Related]
17. The advantageous role of annexin A1 in cardiovascular disease.
de Jong R; Leoni G; Drechsler M; Soehnlein O
Cell Adh Migr; 2017 May; 11(3):261-274. PubMed ID: 27860536
[TBL] [Abstract][Full Text] [Related]
18. Effects of hyperosmolarity on annexin A1 on ocular surface epithelium in vitro.
Fernandez-Torres MA; Lledó VE; Perez de Lara MJ; Guzman-Aranguez A
Exp Eye Res; 2022 Nov; 224():109245. PubMed ID: 36087761
[TBL] [Abstract][Full Text] [Related]
19. Annexin A1 and the Resolution of Inflammation: Modulation of Neutrophil Recruitment, Apoptosis, and Clearance.
Sugimoto MA; Vago JP; Teixeira MM; Sousa LP
J Immunol Res; 2016; 2016():8239258. PubMed ID: 26885535
[TBL] [Abstract][Full Text] [Related]
20. The Annexin A1/FPR2 pathway controls the inflammatory response and bacterial dissemination in experimental pneumococcal pneumonia.
Machado MG; Tavares LP; Souza GVS; Queiroz-Junior CM; Ascenção FR; Lopes ME; Garcia CC; Menezes GB; Perretti M; Russo RC; Teixeira MM; Sousa LP
FASEB J; 2020 Feb; 34(2):2749-2764. PubMed ID: 31908042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
